Display options
Cite
Mogensen MB, Loft A, Aznar M, et al. FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Res. 2017;7(1):56doi: 10.1186/s13550-017-0302-3.
Mogensen, M. B., Loft, A., Aznar, M., Axelsen, T., Vainer, B., Osterlind, K., & Kjaer, A. (2017). FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI research, 7(1), 56. https://doi.org/10.1186/s13550-017-0302-3
Mogensen, Marie Benzon, et al. "FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study." EJNMMI research vol. 7,1 (2017): 56. doi: https://doi.org/10.1186/s13550-017-0302-3
Mogensen MB, Loft A, Aznar M, Axelsen T, Vainer B, Osterlind K, Kjaer A. FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Res. 2017 Dec;7(1):56. doi: 10.1186/s13550-017-0302-3. Epub 2017 Jul 10. PMID: 28695424; PMCID: PMC5503853.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2017 Dec;7(1):56. doi: 10.1186/s13550-017-0302-3. Epub 2017 Jul 10.

FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study.

EJNMMI research

Marie Benzon Mogensen, Annika Loft, Marianne Aznar, Thomas Axelsen, Ben Vainer, Kell Osterlind, Andreas Kjaer

Affiliations

  1. Department of Oncology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark. [email protected].
  2. Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
  3. Department of Oncology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
  4. Department of Radiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  5. Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

PMID: 28695424 PMCID: PMC5503853 DOI: 10.1186/s13550-017-0302-3

Abstract

BACKGROUND: Fluoro-L-thymidine (FLT) is a positron emission tomography/computed tomography (PET/CT) tracer which reflects proliferative activity in a cancer lesion. The main objective of this prospective explorative study was to evaluate whether FLT-PET can be used for the early evaluation of treatment response in colorectal cancer patients (CRC) with liver metastases. Patients with metastatic CRC having at least one measurable (>1 cm) liver metastasis receiving first-line chemotherapy were included. A FLT-PET/CT scan was performed at baseline and after the first treatment. The maximum and mean standardised uptake values (SUV

RESULTS: Thirty-nine consecutive patients were included of which 27 were evaluable. Dropout was mainly due to disease complications. Nineteen patients (70%) had a partial response, seven (26%) had stable disease and one (4%) had progressive disease. A total of 23 patients (85%) had a decrease in FLT uptake following the first treatment. The patient with progressive disease had the highest increase in FLT uptake in SUV

CONCLUSIONS: No correlation was found between early changes in FLT uptake after the first cycle of treatment and the response evaluated from subsequent CT scans. It seems unlikely that FLT-PET can be used on its own for the early response evaluation of metastatic CRC.

Keywords: Colorectal cancer; Early evaluation; FLT-PET; Molecular imaging; [18 F]-3′-Deoxy-3′-fluorothymidine

References

  1. Mol Cancer Ther. 2008 Sep;7(9):3112-21 - PubMed
  2. PLoS One. 2013 Dec 26;8(12 ):e85126 - PubMed
  3. J Nucl Med. 2013 Aug;54(8):1209-16 - PubMed
  4. Pharm Stat. 2014 Sep-Oct;13(5):286-93 - PubMed
  5. Lancet Oncol. 2010 Jan;11(1):92-102 - PubMed
  6. AJR Am J Roentgenol. 2012 Oct;199(4):809-15 - PubMed
  7. Mol Imaging Biol. 2012 Oct;14 (5):617-24 - PubMed
  8. J Nucl Med. 2004 Apr;45(4):695-700 - PubMed
  9. J Nucl Med. 2009 May;50 Suppl 1:122S-50S - PubMed
  10. Eur J Cancer. 2012 Dec;48(18):3499-513 - PubMed
  11. Eur J Surg Oncol. 2015 Jul;41(7):868-74 - PubMed
  12. Neuro Oncol. 2013 Jan;15(1):41-56 - PubMed
  13. PLoS One. 2010 Sep 24;5(9):e12965 - PubMed
  14. PLoS One. 2014 Mar 13;9(3):e91387 - PubMed
  15. Eur J Nucl Med Mol Imaging. 2004 Dec;31(12 ):1659-72 - PubMed
  16. J Nucl Med. 2013 Mar;54(3):424-30 - PubMed
  17. Am J Clin Oncol. 1982 Dec;5(6):649-55 - PubMed
  18. J Clin Oncol. 2006 Jan 20;24(3):394-400 - PubMed
  19. Lancet. 2014 Apr 26;383(9927):1490-502 - PubMed
  20. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  21. Cancer Chemother Pharmacol. 2011 Aug;68(2):389-98 - PubMed
  22. Phys Med Biol. 2012 Jun 7;57(11):3419-33 - PubMed
  23. Magn Reson Imaging. 2006 Sep;24(7):843-7 - PubMed
  24. Oncotarget. 2015 Nov 10;6(35):37486-99 - PubMed
  25. JAMA. 2009 Dec 2;302(21):2338-44 - PubMed
  26. Oncologist. 2007 Jul;12(7):825-39 - PubMed
  27. J Clin Oncol. 2009 Dec 1;27(34):5727-33 - PubMed
  28. BMC Cancer. 2013 Apr 01;13:168 - PubMed
  29. Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1436-48 - PubMed
  30. Cancer Res. 2006 Sep 1;66(17 ):8558-64 - PubMed
  31. World J Nucl Med. 2012 May;11(2):65-9 - PubMed
  32. Nucl Med Biol. 2009 Aug;36(6):681-6 - PubMed
  33. Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):431-56 - PubMed

Publication Types

Grant support